• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Cardinal Health Inc.

    11/13/24 5:15:49 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care
    Get the next $CAH alert in real time by email
    FWP 1 d901113dfwp.htm FWP FWP

    Free Writing Prospectus

    Filed Pursuant to Rule 433

    Registration Statement No. 333-268237

    Dated November 13, 2024

    Cardinal Health, Inc.

    Pricing Term Sheet

    $2,900,000,000 aggregate principal amount of Notes offered

    4.700% Notes due 2026 (the “2026 Notes”)

    5.000% Notes due 2029 (the “2029 Notes”)

    5.350% Notes due 2034 (the “2034 Notes”)

    5.750% Notes due 2054 (the “2054 Notes”)

     

    Issuer:    Cardinal Health, Inc.
    Expected Ratings (Moody’s / S&P / Fitch)*:    Baa2 / BBB / BBB (S/S/S)
    Trade Date:    November 13, 2024
    Settlement Date**:    T+7; November 22, 2024
    Joint Book-Running Managers:   

    BofA Securities, Inc.
    J.P. Morgan Securities LLC

    Wells Fargo Securities, LLC

    MUFG Securities Americas Inc.

    Scotia Capital (USA) Inc.

    PNC Capital Markets LLC

    Senior Co-Managers:   

    Deutsche Bank Securities Inc.

    HSBC Securities (USA) Inc.

    Co-Managers:   

    Standard Chartered Bank

    Huntington Securities, Inc.

    Truist Securities, Inc.

    U.S. Bancorp Investments, Inc.

    2026 Notes

     

    Principal Amount Offered:

       $500,000,000

    Maturity Date:

      

    November 15, 2026

    Coupon:

       4.700%


    Price to Public:    99.926% of principal amount
    Net Proceeds to Issuer (after the Underwriting Discount but before expenses):    $497,880,000
    Benchmark Treasury:    4.125% due October 31, 2026
    Benchmark Treasury Price / Yield:    99-22 1/8 / 4.290%
    Spread to Benchmark Treasury:    +45 basis points
    Yield to Maturity:    4.740%
    Interest Payment Dates:    Semi-annually on May 15 and November 15, commencing May 15, 2025
    Make-whole Call:    At any time prior to November 15, 2026 at a discount rate of Treasury plus 10 basis points
    CUSIP/ISIN:    14149Y BQ0 / US14149YBQ08

    2029 Notes

     

    Principal Amount Offered:    $750,000,000
    Maturity Date:    November 15, 2029
    Coupon:    5.000%
    Price to Public:    99.966% of principal amount
    Net Proceeds to Issuer (after the Underwriting Discount but before expenses):    $745,245,000
    Benchmark Treasury:    4.125% due October 31, 2029
    Benchmark Treasury Price / Yield:    99-06 / 4.308%
    Spread to Benchmark Treasury:    +70 basis points
    Yield to Maturity:    5.008%
    Interest Payment Dates:    Semi-annually on May 15 and November 15, commencing May 15, 2025

     

    2


    Make-whole Call:    At any time prior to October 15, 2029 at a discount rate of Treasury plus 15 basis points
    Par Call:    On or after October 15, 2029 at 100%
    CUSIP/ISIN:    14149Y BR8 / US14149YBR80

    2034 Notes

     

    Principal Amount Offered:    $1,000,000,000
    Maturity Date:    November 15, 2034
    Coupon:    5.350%
    Price to Public:    99.719% of principal amount
    Net Proceeds to Issuer (after the Underwriting Discount but before expenses):    $990,690,000
    Benchmark Treasury:    4.250% due November 15, 2034
    Benchmark Treasury Price / Yield:    98-11 / 4.457%
    Spread to Benchmark Treasury:    +93 basis points
    Yield to Maturity:    5.387%
    Interest Payment Dates:    Semi-annually on May 15 and November 15, commencing May 15, 2025
    Make-whole Call:    At any time prior to August 15, 2034 at a discount rate of Treasury plus 15 basis points
    Par Call:    On or after August 15, 2034 at 100%
    CUSIP/ISIN:    14149Y BS6/ US14149YBS63

    2054 Notes

     

    Principal Amount Offered:    $650,000,000
    Maturity Date:    November 15, 2054
    Coupon:    5.750%

     

    3


    Price to Public:    99.605% of principal amount
    Net Proceeds to Issuer (after the Underwriting Discount but before expenses):    $641,745,000
    Benchmark Treasury:    4.250% due August 15, 2054
    Benchmark Treasury Price / Yield:    93-19+ / 4.648%
    Spread to Benchmark Treasury:    +113 basis points
    Yield to Maturity:    5.778%
    Interest Payment Dates:    Semi-annually on May 15 and November 15, commencing May 15, 2025
    Make-whole Call:    At any time prior to May 15, 2054 at a discount rate of Treasury plus 20 basis points
    Par Call:    On or after May 15, 2054 at 100%
    CUSIP/ISIN:    14149Y BT4 / US14149YBT47

     

    *

    Note: The ratings above are not a recommendation to buy, sell or hold the securities. The ratings may be subject to revision or withdrawal at any time. Each of the ratings above should be evaluated independently of any other securities rating.

    **

    Note: We expect that delivery of the notes will be made against payment therefor on or about November 22, 2024, which will be the seventh business day following the date of pricing of the notes, or “T+7.” Under Rule 15c6-1 of the Securities Exchange Act of 1934, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes prior to the sixth business day before delivery will be required, by virtue of the fact that the notes initially will settle in T+7, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes prior to the sixth business day before delivery should consult their advisors.

    The issuer has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (“SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling BofA Securities, Inc. at +1-800-294-1322, J.P. Morgan Securities LLC at +1-212-834-4533 or Wells Fargo Securities, LLC at +1-800-645-3751.

     

    4


    ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.

     

    5

    Get the next $CAH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAH

    DatePrice TargetRatingAnalyst
    1/9/2026Neutral → Buy
    Citigroup
    12/9/2025$243.00Overweight
    Barclays
    6/3/2025$179.00Equal Weight → Overweight
    Wells Fargo
    2/5/2025$140.00 → $150.00Hold → Buy
    Jefferies
    1/8/2025$130.00 → $144.00Hold → Buy
    TD Cowen
    1/7/2025$140.00In-line → Outperform
    Evercore ISI
    1/6/2025$132.00 → $145.00Neutral → Buy
    BofA Securities
    12/13/2024$101.00 → $127.00Underweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $CAH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Feb. 12, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on April 15, 2026 to shareholders of record at the close of business on April 1, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc

    2/12/26 4:45:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook

    Revenue increased 19% to $65.6 billionGAAP1 operating earnings increased 29% to $707 million; GAAP diluted EPS increased 19% to $1.97Non-GAAP operating earnings increased 38% to $877 million; non-GAAP diluted EPS increased 36% to $2.63Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $10.15 to $10.35Cardinal Health completes annual baseline share repurchase of $750 millionCardinal Health reaches targeted leverage range3DUBLIN, Ohio, Feb. 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2026 revenues of $65.6 billion, an increase of 19% from the second quarter of fiscal year 2025. Second quarter GAAP operating earnings increased 29%

    2/5/26 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Raises Fiscal 2026 Outlook and Highlights Strategic Progress During J.P. Morgan Healthcare Conference Presentation

    Raising Fiscal 2026 Outlook: Cardinal Health is increasing expectations for fiscal year 2026 non-GAAP diluted earnings per share (EPS)1 to at least $10.00, from its prior guidance range of $9.65 to $9.85Accelerating Specialty Growth: The company expects that its Specialty revenues will surpass $50 billion in fiscal 2026, marking a 16% compounded annual growth rate (CAGR) over three years2Successfully Navigating IRA Changes: The company confirms the successful transition of its manufacturer distribution service agreements for all branded pharmaceutical products impacted by the 2026 Medicare Drug Price Negotiation ProgramIntroducing ContinuCare™ Pathway: The company's direct-to-patient at-Home

    1/13/26 6:50:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hall Patricia Hemingway sold $918,880 worth of shares (4,000 units at $229.72), decreasing direct ownership by 12% to 28,264 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    2/10/26 4:13:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Chief Human Resources Officer Pitteroff Valerie Christine was granted 3,982 shares, increasing direct ownership by 99% to 8,022 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    1/20/26 7:21:53 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    New insider Pitteroff Valerie Christine claimed ownership of 4,503 shares (SEC Form 3)

    3 - CARDINAL HEALTH INC (0000721371) (Issuer)

    1/7/26 4:10:22 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $CAH
    SEC Filings

    View All

    Cardinal Health upgraded by Citigroup

    Citigroup upgraded Cardinal Health from Neutral to Buy

    1/9/26 8:24:26 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Barclays initiated coverage on Cardinal Health with a new price target

    Barclays initiated coverage of Cardinal Health with a rating of Overweight and set a new price target of $243.00

    12/9/25 8:43:24 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Cardinal Health from Equal Weight to Overweight and set a new price target of $179.00

    6/3/25 7:24:57 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form 10-Q filed by Cardinal Health Inc.

    10-Q - CARDINAL HEALTH INC (0000721371) (Filer)

    2/5/26 8:47:09 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    2/5/26 6:47:19 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    1/13/26 6:53:33 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Financials

    Live finance-specific insights

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Feb. 12, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on April 15, 2026 to shareholders of record at the close of business on April 1, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuc

    2/12/26 4:45:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports Second Quarter Fiscal Year 2026 Results and Raises Outlook

    Revenue increased 19% to $65.6 billionGAAP1 operating earnings increased 29% to $707 million; GAAP diluted EPS increased 19% to $1.97Non-GAAP operating earnings increased 38% to $877 million; non-GAAP diluted EPS increased 36% to $2.63Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $10.15 to $10.35Cardinal Health completes annual baseline share repurchase of $750 millionCardinal Health reaches targeted leverage range3DUBLIN, Ohio, Feb. 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2026 revenues of $65.6 billion, an increase of 19% from the second quarter of fiscal year 2025. Second quarter GAAP operating earnings increased 29%

    2/5/26 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Nov. 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on January 15, 2026 to shareholders of record at the close of business on January 2, 2026. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of

    11/4/25 4:45:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Leadership Updates

    Live Leadership Updates

    View All

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Carlisle Companies Announces Leadership Appointments

    Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu

    5/16/25 4:05:00 PM ET
    $CAH
    $CSL
    $SUM
    Other Pharmaceuticals
    Health Care
    Specialty Chemicals
    Industrials

    Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

    DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e

    3/10/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/13/24 5:01:02 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    1/30/24 1:39:03 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/14/23 12:37:58 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care